Debiopharm Group - Product Pipeline Review - Q1 2011
Summary
Global Market Direct’s pharmaceuticals report, “Debiopharm Group - Product Pipeline Review - Q1 2011” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
Summary
Global Market Direct’s pharmaceuticals report, “Debiopharm Group - Product Pipeline Review - Q1 2011” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- Debiopharm Group - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Debiopharm Group human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Debiopharm Group with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Debiopharm Group’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
- Evaluate Debiopharm Group’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Debiopharm Group in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Debiopharm Group’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Debiopharm Group.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Debiopharm Group and identify potential opportunities in those areas.
Table of Contents
List of Tables
List of Figures
Debiopharm Group Snapshot
Debiopharm Group Overview
Key Information
Key Facts
Debiopharm Group – Research and Development Overview
Key Therapeutic Areas
Debiopharm Group – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Debiopharm Group – Pipeline Products Glance
Debiopharm Group – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Debiopharm Group Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Debiopharm Group–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Debiopharm Group – Drug Profiles
Pamorelin
Product Description
Mechanism of Action
R&D Progress
Sanvar
Product Description
Mechanism of Action
R&D Progress
Debio 025 + Peginterferon Alpha-2a + Ribavirin
Product Description
Mechanism of Action
R&D Progress
Debio 9902
Product Description
Mechanism of Action
R&D Progress
DX-890
Product Description
Mechanism of Action
R&D Progress
DACH-Platin Micelle
Product Description
Mechanism of Action
R&D Progress
Debio 0827
Product Description
Mechanism of Action
R&D Progress
Debio 0932
Product Description
Mechanism of Action
R&D Progress
Debio 0617
Product Description
Mechanism of Action
R&D Progress
Debio 0719
Product Description
Mechanism of Action
R&D Progress
Debio 0928
Product Description
Mechanism of Action
R&D Progress
Debio 0931
Product Description
Mechanism of Action
R&D Progress
Debio 0932
Product Description
Mechanism of Action
R&D Progress
PAT-SC1
Product Description
Mechanism of Action
R&D Progress
Debio 0721
Product Description
R&D Progress
Debio 0826
Product Description
Mechanism of Action
R&D Progress
Debio 0929
Product Description
Mechanism of Action
R&D Progress
Debio 0930
Product Description
Mechanism of Action
R&D Progress
Debiopharm Group – Pipeline Analysis
Debiopharm Group – Pipeline Products by Therapeutic Class
Debiopharm Group - Pipeline Products By Target
Debiopharm Group – Pipeline Products by Route of Administration
Debiopharm Group – Pipeline Products by Molecule Type
Debiopharm Group – Recent Pipeline Updates
Debiopharm Group - Dormant Projects
Debiopharm Group - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Debio 0614
Debiopharm Group – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Jun 06, 2010: Curis Achieves Phase I Milestone Under Hsp90 Collaboration With Debiopharm
Jun 06, 2010: Curis Achieves Phase I Milestone Under Hsp90 Collaboration With Debiopharm
Apr 27, 2010: Debiopharm Begins Phase I Clinical Trial With Debio 0932
Apr 27, 2010: Debiopharm Begins Phase I Clinical Trial With Debio 0932
Feb 12, 2010: Curis Achieves Milestone With Debiopharm Receiving Approval From France's Regulatory Authority For Debio 0932
Feb 09, 2010: Novartis Gains Rights To Develop And Market Debio 025
Feb 09, 2010: Novartis Gains Rights To Develop And Market Debio 025
Dec 24, 2009: Curis Announces Preclinical Data Results Of Debio 0932 (CUDC-305) For The Treatment Of Non-Small Cell Lung Cancer
Jun 10, 2009: Curis Publishes Preclinical Data For Heat Shock Protein 90 Molecule CUDC-305 In Clinical Cancer Research
Apr 30, 2009: Debiopharm Group Starts Phase IIb Study For Debio 025 .
Financial Deals Landscape
Debiopharm Group, Deals Volume Summary, 2004 to YTD 2011
Debiopharm Group, Deals Summary By Region, 2004 to YTD 2011
Debiopharm Group, Deals Summary, 2004 to YTD 2011
Debiopharm Group Detailed Deal Summary
Asset Purchase
Patrys Acquires Rights Of SC1 From Debiovision
Venture Financing
TcLand Expression Secures $12.04 Million In Series A Financing
Pfizer Enters Into Co-Development Agreement With Debiopharm
Debiopharm Enters Into Agreement With MSM Protein Technologies
Debiopharm Enters Into Distribution Agreement With Mepha Pharma
Debiopharm Enters Into Research Agreement With Ecole Polytechnique Federale de Lausanne
Debiopharm Enters Into Co-Marketing Agreement
Debiopharm Enters Into Research Agreement With Kirin Brewery
Debiopharm Enters Into Co-Development Agreement With Aurigene
Debiopharm Enters Into Co-Development Agreement With TcLand
Licensing Agreements
Ipsen Enters Into License Agreement With Debiopharm
Curis Enters Into Worldwide License Agreement With Debiopharm
Debiopharm Enters Into Licensing Agreement With Mercury Therapeutics
Debiopharm Group Signs An Agreement With Moffitt Cancer Center
Debiopharm Enters Into Licensing Agreement With Aurigene
Debiopharm Group Enters Into Licensing Agreement With PharmaLeads
Debiopharm Enters Into Licensing Agreement With Medical Futures
Ipsen Extends Its Agreement With Debiopharm
Debiopharm Enters Into Licensing Agreement With NanoCarrier
Ranbaxy Laboratories Enters Into Licensing Agreement With Debiopharm For Sanvar
Debiopharm Enters Into Licensing Agreement With Ems Sigma Pharma
Debiopharm Enters Into Licensing Agreement With Tzamal Bio-Pharma
Debiopharm Enters Into Licensing Agreement With LG Life Sciences
Debiopharm Enters Into Licensing Agreement With MedImmune
Salix Pharmaceuticals Enters Into Licensing Agreement With Debiovision
Debiopharm Enters Into Licensing Agreement with Sigma-Tau
Dyax Amends Licensing Agreement With Debiopharm
Debiopharm Enters Into Licensing Agreement With DeveloGen
GPC Biotech Enters Into Licensing Agreement With Debiopharm
Watson Pharmaceuticals Enters Into Licensing Agreement With Debiopharm
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Debiopharm Group – Pipeline by Therapy Area and Indication, 2011
Debiopharm Group – Pipeline by Stage of Development, 2011
Debiopharm Group – Monotherapy Products in Pipeline, 2011
Debiopharm Group – Combination Treatment Modalities in Pipeline, 2011
Debiopharm Group – Filed, 2011
Debiopharm Group - Phase II, 2011
Debiopharm Group - Phase I, 2011
Debiopharm Group - Pipeline By Therapeutic Class, 2011
Debiopharm Group - Pipeline By Target, 2011
Debiopharm Group – Pipeline By Route of Administration, 2011
Debiopharm Group – Pipeline By Molecule Type, 2011
Debiopharm Group – Recent Pipeline Updates, 2011
Debiopharm Group - Dormant Developmental Projects, 2010
Debiopharm Group - Discontinued Pipeline Products, 2010
Debiopharm Group, Other Locations
Debiopharm Group, Subsidiaries
Debiopharm Group, Deals Summary, 2004 to YTD 2011
Debiopharm Group, Deals Summary by Region, 2004 to YTD 2011
Debiopharm Group, Deals Summary, 2004 to YTD 2011
Debiopharm Group, Deals Summary, 2004 to YTD 2011
LIST OF FIGURES
Debiopharm Group – Pipeline by Therapy Area and Indication, 2011
Debiopharm Group – Pipeline by Stage of Development, 2011
Debiopharm Group – Monotherapy Products in Pipeline, 2011
Debiopharm Group – Combination Treatment Modalities in Pipeline, 2011
Debiopharm Group – Pipeline By Therapeutic Class, 2011
Debiopharm Group - Pipeline By Target, 2011
Debiopharm Group – Pipeline By Route of Administration, 2011
Debiopharm Group – Pipeline By Molecule Type, 2011
List of Tables
List of Figures
Debiopharm Group Snapshot
Debiopharm Group Overview
Key Information
Key Facts
Debiopharm Group – Research and Development Overview
Key Therapeutic Areas
Debiopharm Group – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Debiopharm Group – Pipeline Products Glance
Debiopharm Group – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Debiopharm Group Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Debiopharm Group–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Debiopharm Group – Drug Profiles
Pamorelin
Product Description
Mechanism of Action
R&D Progress
Sanvar
Product Description
Mechanism of Action
R&D Progress
Debio 025 + Peginterferon Alpha-2a + Ribavirin
Product Description
Mechanism of Action
R&D Progress
Debio 9902
Product Description
Mechanism of Action
R&D Progress
DX-890
Product Description
Mechanism of Action
R&D Progress
DACH-Platin Micelle
Product Description
Mechanism of Action
R&D Progress
Debio 0827
Product Description
Mechanism of Action
R&D Progress
Debio 0932
Product Description
Mechanism of Action
R&D Progress
Debio 0617
Product Description
Mechanism of Action
R&D Progress
Debio 0719
Product Description
Mechanism of Action
R&D Progress
Debio 0928
Product Description
Mechanism of Action
R&D Progress
Debio 0931
Product Description
Mechanism of Action
R&D Progress
Debio 0932
Product Description
Mechanism of Action
R&D Progress
PAT-SC1
Product Description
Mechanism of Action
R&D Progress
Debio 0721
Product Description
R&D Progress
Debio 0826
Product Description
Mechanism of Action
R&D Progress
Debio 0929
Product Description
Mechanism of Action
R&D Progress
Debio 0930
Product Description
Mechanism of Action
R&D Progress
Debiopharm Group – Pipeline Analysis
Debiopharm Group – Pipeline Products by Therapeutic Class
Debiopharm Group - Pipeline Products By Target
Debiopharm Group – Pipeline Products by Route of Administration
Debiopharm Group – Pipeline Products by Molecule Type
Debiopharm Group – Recent Pipeline Updates
Debiopharm Group - Dormant Projects
Debiopharm Group - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Debio 0614
Debiopharm Group – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Jun 06, 2010: Curis Achieves Phase I Milestone Under Hsp90 Collaboration With Debiopharm
Jun 06, 2010: Curis Achieves Phase I Milestone Under Hsp90 Collaboration With Debiopharm
Apr 27, 2010: Debiopharm Begins Phase I Clinical Trial With Debio 0932
Apr 27, 2010: Debiopharm Begins Phase I Clinical Trial With Debio 0932
Feb 12, 2010: Curis Achieves Milestone With Debiopharm Receiving Approval From France's Regulatory Authority For Debio 0932
Feb 09, 2010: Novartis Gains Rights To Develop And Market Debio 025
Feb 09, 2010: Novartis Gains Rights To Develop And Market Debio 025
Dec 24, 2009: Curis Announces Preclinical Data Results Of Debio 0932 (CUDC-305) For The Treatment Of Non-Small Cell Lung Cancer
Jun 10, 2009: Curis Publishes Preclinical Data For Heat Shock Protein 90 Molecule CUDC-305 In Clinical Cancer Research
Apr 30, 2009: Debiopharm Group Starts Phase IIb Study For Debio 025 .
Financial Deals Landscape
Debiopharm Group, Deals Volume Summary, 2004 to YTD 2011
Debiopharm Group, Deals Summary By Region, 2004 to YTD 2011
Debiopharm Group, Deals Summary, 2004 to YTD 2011
Debiopharm Group Detailed Deal Summary
Asset Purchase
Patrys Acquires Rights Of SC1 From Debiovision
Venture Financing
TcLand Expression Secures $12.04 Million In Series A Financing
Pfizer Enters Into Co-Development Agreement With Debiopharm
Debiopharm Enters Into Agreement With MSM Protein Technologies
Debiopharm Enters Into Distribution Agreement With Mepha Pharma
Debiopharm Enters Into Research Agreement With Ecole Polytechnique Federale de Lausanne
Debiopharm Enters Into Co-Marketing Agreement
Debiopharm Enters Into Research Agreement With Kirin Brewery
Debiopharm Enters Into Co-Development Agreement With Aurigene
Debiopharm Enters Into Co-Development Agreement With TcLand
Licensing Agreements
Ipsen Enters Into License Agreement With Debiopharm
Curis Enters Into Worldwide License Agreement With Debiopharm
Debiopharm Enters Into Licensing Agreement With Mercury Therapeutics
Debiopharm Group Signs An Agreement With Moffitt Cancer Center
Debiopharm Enters Into Licensing Agreement With Aurigene
Debiopharm Group Enters Into Licensing Agreement With PharmaLeads
Debiopharm Enters Into Licensing Agreement With Medical Futures
Ipsen Extends Its Agreement With Debiopharm
Debiopharm Enters Into Licensing Agreement With NanoCarrier
Ranbaxy Laboratories Enters Into Licensing Agreement With Debiopharm For Sanvar
Debiopharm Enters Into Licensing Agreement With Ems Sigma Pharma
Debiopharm Enters Into Licensing Agreement With Tzamal Bio-Pharma
Debiopharm Enters Into Licensing Agreement With LG Life Sciences
Debiopharm Enters Into Licensing Agreement With MedImmune
Salix Pharmaceuticals Enters Into Licensing Agreement With Debiovision
Debiopharm Enters Into Licensing Agreement with Sigma-Tau
Dyax Amends Licensing Agreement With Debiopharm
Debiopharm Enters Into Licensing Agreement With DeveloGen
GPC Biotech Enters Into Licensing Agreement With Debiopharm
Watson Pharmaceuticals Enters Into Licensing Agreement With Debiopharm
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Debiopharm Group – Pipeline by Therapy Area and Indication, 2011
Debiopharm Group – Pipeline by Stage of Development, 2011
Debiopharm Group – Monotherapy Products in Pipeline, 2011
Debiopharm Group – Combination Treatment Modalities in Pipeline, 2011
Debiopharm Group – Filed, 2011
Debiopharm Group - Phase II, 2011
Debiopharm Group - Phase I, 2011
Debiopharm Group - Pipeline By Therapeutic Class, 2011
Debiopharm Group - Pipeline By Target, 2011
Debiopharm Group – Pipeline By Route of Administration, 2011
Debiopharm Group – Pipeline By Molecule Type, 2011
Debiopharm Group – Recent Pipeline Updates, 2011
Debiopharm Group - Dormant Developmental Projects, 2010
Debiopharm Group - Discontinued Pipeline Products, 2010
Debiopharm Group, Other Locations
Debiopharm Group, Subsidiaries
Debiopharm Group, Deals Summary, 2004 to YTD 2011
Debiopharm Group, Deals Summary by Region, 2004 to YTD 2011
Debiopharm Group, Deals Summary, 2004 to YTD 2011
Debiopharm Group, Deals Summary, 2004 to YTD 2011
LIST OF FIGURES
Debiopharm Group – Pipeline by Therapy Area and Indication, 2011
Debiopharm Group – Pipeline by Stage of Development, 2011
Debiopharm Group – Monotherapy Products in Pipeline, 2011
Debiopharm Group – Combination Treatment Modalities in Pipeline, 2011
Debiopharm Group – Pipeline By Therapeutic Class, 2011
Debiopharm Group - Pipeline By Target, 2011
Debiopharm Group – Pipeline By Route of Administration, 2011
Debiopharm Group – Pipeline By Molecule Type, 2011
